Aging
Navigate
Submit an Article
Research Paper|Volume 13, Issue 7|pp 10354—10368

Identification of GSPT1 as prognostic biomarker and promoter of malignant colon cancer cell phenotypes via the GSK-3β/CyclinD1 pathway

Xuan Long1, Lijun Zhao1, Guoqiang Li1, Ziwei Wang2, Zhigang Deng1
  • 1Department of General Surgery, Mianyang Central Hospital, Mianyang Central Hospital of Chongqing Medical University, Mianyang 621000, Sichuan Province, P.R. China
  • 2Department of Gastroenterological Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing Medical University, Yuzhong 400016, Chongqing, P.R. China
Received: August 22, 2020Accepted: January 21, 2021Published: April 4, 2021
https://doi.org/10.18632/aging.202796

Copyright: © 2021 Long et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Colon cancer is the third most common malignant tumor and its mortality rate ranks fourth among all malignant tumor types. Bioinformatics analysis has shown that GSPT1 is dysregulated in colon cancer and is associated with tumor progression. However, the underlying mechanism remains unclear. To address this research gap, we examined the impact of GSPT1 on cell proliferation, apoptosis, migration, and invasion in vitro as well as tumor growth in vivo in colon cancer by using a Cell Counting Kit-8 assay, flow cytometry, transwell migration assay, transwell invasion assay, and tumor xenograft model-based analysis, respectively. GSPT1 was significantly up-regulated in colon cancer tissues and cell lines. High GSPT1 expression was correlated with a larger tumor size. Depletion of GSPT1 suppressed cell proliferation, migration, and invasion-induced colon cancer cell apoptosis in vitro and restrained tumorigenicity in vivo in HCT116 colon cancer cells. Taken together, our findings suggest that the GSPT1/GSK pathway exerts tumor-promoting actions in colon cancer oncogenesis and progression. The GSPT1/GSK pathway may thus be an effective target for controlling colon cancer.